The route belongs to the exact testosterone product

Begin with the full product name

Testosterone is the hormone name. Cypionate and enanthate identify different ester forms appearing in different medicines. A webpage that shortens both names to testosterone injection has removed information needed to identify the product. Packaging and route statements should therefore be read with the full medicine name rather than treated as generic instructions for a category.

The Depo-Testosterone label identifies testosterone cypionate for intramuscular use. The Xyosted record identifies testosterone enanthate for subcutaneous use. This pair is useful as an identity example, not a recommendation between treatments. It does not establish that either product is what an online service dispenses or that their instructions can be exchanged.

A route statement answers a narrower question than suitability

Intramuscular means into muscle, while subcutaneous means beneath the skin. Those definitions help readers understand a discussion with a clinician. They do not identify a suitable location, device, technique or treatment amount for a person. Those details require instruction for the actual prescribed medicine from the professionals providing care.

The inspected Depo document specifies intramuscular use only. Xyosted's label specifies its own subcutaneous product. Reading those records correctly does not make either route preferable for every patient. The intended use, formulation, medical history and prescriber's assessment remain separate considerations. Avoid interpreting a familiar route abbreviation as proof that a product matches a previous prescription.

Off-label use is different from approval of a compounded preparation

FDA's explanation of off-label use concerns an approved drug used in a way outside its approved labeling. Clinicians generally may prescribe an approved medicine for an unapproved use when they judge it medically appropriate. FDA has not thereby determined that the unapproved use is safe and effective. A reader can ask what evidence supports the proposal and what uncertainties remain.

A compounded medicine presents an additional distinction: FDA states that the finished compounded drug is not FDA-approved. Calling a proposed route off-label should not imply that an unidentified compounded preparation otherwise has the approval of a branded reference product. Both the preparation's status and the proposed use need an accurate explanation.

Read a provider FAQ as an offer description

CoreAge's TRT page names cypionate, describes the offer as compounded, and discusses intramuscular or subcutaneous options in its FAQ. It leaves the actual dispensing pharmacy and complete formulation unstated. That text records what the company advertises; it is not the supplied prescription label or a head-to-head clinical comparison of routes.

Our CoreAge review explains the current offer without borrowing Depo's product identity. Ask the clinician which preparation is proposed, what route is intended and how that choice is supported for the particular situation. If the explanation and pharmacy information appear inconsistent, have the care team resolve them rather than selecting the preferred wording yourself.

It is reasonable to request that explanation in writing so the pharmacy and prescribing practice can address the same identified preparation.

A familiar concentration cannot fill in the route

The concentration on a sales page describes an amount within liquid. It does not establish the route, ingredients, device or professional training required. The concentration guide separates those meanings without worked calculations. A match between two concentration numbers cannot prove that two products have identical instructions or have been evaluated in the same way.

The ingredient guide similarly keeps the full formulation attached to the product record. A reader need not become a pharmaceutical chemist to recognize missing information. It is enough to ask the pharmacist to identify the dispensed preparation and the prescriber to explain the intended use. Similar words on two websites do not settle those questions.

Current safety information still needs professional interpretation

Route questions should not crowd out the reason for treatment and its follow-up. The July 2026 Endocrine Society statement stresses accurate diagnosis, assessment of contributors and continuing risk review. A route discussion cannot establish that nonspecific symptoms are caused by testosterone deficiency or that a medicine is appropriate simply because it can be administered conveniently.

The exact Depo label includes blood-pressure and blood-count precautions. The responsible clinician should explain the monitoring relevant to the actual prescription, including response, unwanted effects and other care. This guide provides no monitoring timetable. It also does not assume that choosing a different route removes systemic concerns or creates a fertility-preservation strategy.

Document what is known and what still needs an answer

Keep the complete medicine name, actual pharmacy information and professional explanation together. If product documents carry different dates, ask which record is relevant to the prescription. Our age-related labeling guide explains the June 2026 FDA request alongside the earlier revision still visible in the inspected Pfizer document. A regulatory update and a supplied product record answer related but different questions.

Our product-record comparison distinguishes verified descriptions from unanswered details. This publication was prepared for the CoreAge Rx network, an affiliation readers should weigh when evaluating its coverage. The relationship does not validate a product, establish a preferred route or amount to a clinical endorsement. A useful conclusion is a precise, understandable professional account of the product and proposed care, with no need for the reader to improvise administration instructions.